Nurix Therapeutics is trading at $15.44, up 4.04%, with the broader market rebound a possible explanation for the November 6 rise. - Search results showed no new company-specific catalyst for the November 6 rise. - Sanofi’s November 3 decision to end the SAR448272 program removed potential future milestones and royalties; coverage linked it to the earlier sell-off, not today’s gain. - Nasdaq rose 1.66% and S&P 500 rose 0.87%, supporting a market-rebound explanation, though biotech-sector context points the other way.